DK2421534T3 - Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin - Google Patents
Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazinInfo
- Publication number
- DK2421534T3 DK2421534T3 DK10714164.0T DK10714164T DK2421534T3 DK 2421534 T3 DK2421534 T3 DK 2421534T3 DK 10714164 T DK10714164 T DK 10714164T DK 2421534 T3 DK2421534 T3 DK 2421534T3
- Authority
- DK
- Denmark
- Prior art keywords
- dimethylphenylsulphanyl
- piperazine
- phenyl
- salts
- liquid formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21454009P | 2009-04-24 | 2009-04-24 | |
DKPA200900531 | 2009-04-24 | ||
PCT/DK2010/050084 WO2010121621A1 (en) | 2009-04-24 | 2010-04-16 | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2421534T3 true DK2421534T3 (da) | 2014-10-13 |
Family
ID=42669509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10714164.0T DK2421534T3 (da) | 2009-04-24 | 2010-04-16 | Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin |
Country Status (35)
Country | Link |
---|---|
US (4) | US8940746B2 (da) |
EP (1) | EP2421534B1 (da) |
JP (1) | JP5722879B2 (da) |
KR (1) | KR101779214B1 (da) |
CN (2) | CN102405048A (da) |
AR (2) | AR076400A1 (da) |
AU (1) | AU2010238946B2 (da) |
BR (1) | BRPI1015338C1 (da) |
CA (1) | CA2759456C (da) |
CL (1) | CL2011002631A1 (da) |
CO (1) | CO6450649A2 (da) |
CR (1) | CR20110554A (da) |
DK (1) | DK2421534T3 (da) |
DO (2) | DOP2011000319A (da) |
EA (1) | EA021122B1 (da) |
ES (1) | ES2512719T3 (da) |
GE (1) | GEP20135938B (da) |
HK (1) | HK1206732A1 (da) |
HR (1) | HRP20140880T1 (da) |
IL (1) | IL215362A0 (da) |
MA (1) | MA33298B1 (da) |
MX (1) | MX2011011119A (da) |
MY (1) | MY155288A (da) |
NZ (1) | NZ596431A (da) |
PL (1) | PL2421534T3 (da) |
PT (1) | PT2421534E (da) |
RS (1) | RS53539B1 (da) |
SG (1) | SG175124A1 (da) |
SI (1) | SI2421534T1 (da) |
SM (1) | SMT201400159B (da) |
TN (1) | TN2011000504A1 (da) |
TW (1) | TWI461224B (da) |
UA (1) | UA106985C2 (da) |
WO (1) | WO2010121621A1 (da) |
ZA (1) | ZA201107731B (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5722879B2 (ja) | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジンの塩の液体製剤 |
CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
CA2916175A1 (en) * | 2013-07-01 | 2015-01-08 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
WO2017137048A1 (en) | 2016-02-08 | 2017-08-17 | H. Lundbeck A/S | Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |
RU2018144248A (ru) | 2016-07-01 | 2020-08-03 | Х. Лундбекк А/С | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта |
CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药(厦门)有限公司 | 沃替西汀β晶型的制备方法 |
GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
KR20220163997A (ko) | 2020-04-03 | 2022-12-12 | 하. 룬드벡 아크티에셀스카브 | 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
DE602004016316D1 (de) | 2003-04-04 | 2008-10-16 | Lundbeck & Co As H | 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer |
CN101472906B (zh) * | 2006-06-16 | 2012-04-25 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
EP2044020B1 (en) * | 2006-06-16 | 2011-05-04 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物 |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
JP5722879B2 (ja) | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジンの塩の液体製剤 |
-
2010
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en active Application Filing
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active IP Right Grant
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 RS RSP20140505 patent/RS53539B1/en unknown
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-09-15 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2421534T3 (da) | Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin | |
DK2398785T3 (da) | Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin | |
DK2470166T3 (da) | Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin | |
CL2014001765A1 (es) | Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. | |
CO6811863A2 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
DK2054394T3 (da) | Piperazinforbindelser med herbicid virkning | |
BR112013033511A2 (pt) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6 - pentahidroxihexil)ethóxi)fenil)butil)carbamimidoil) pirazina-2-carboxamida | |
IL216280A0 (en) | Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4-(dimethylamino)butyl 2-(4-(2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate | |
DK3252069T3 (da) | (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-oner til behandling af sygdomme | |
BRPI0921596A2 (pt) | Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina | |
HUE041725T2 (hu) | (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya | |
CY1118886T1 (el) | Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης | |
DK2753306T3 (da) | Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat | |
ITMI20110647A1 (it) | Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib. | |
DK2129377T3 (da) | Flydende formuleringer af salte af 4-[2-(4-methylphenylsulfanyl)phenyl]piperidin | |
CY1115793T1 (el) | Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης | |
TH148782B (th) | รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate) |